OrthoPediatrics (NASDAQ:KIDS) Reaches New 52-Week Low - Time to Sell?

OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) reached a new 52-week low on Tuesday . The stock traded as low as $19.52 and last traded at $20.62, with a volume of 158156 shares trading hands. The stock had previously closed at $19.96.

Analyst Upgrades and Downgrades

KIDS has been the topic of a number of recent research reports. Truist Financial decreased their target price on OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Stifel Nicolaus decreased their target price on OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, March 5th. Piper Sandler decreased their target price on OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. Needham & Company LLC reaffirmed a "buy" rating and issued a $42.00 target price on shares of OrthoPediatrics in a report on Thursday, May 8th. Finally, Lake Street Capital started coverage on OrthoPediatrics in a report on Monday, April 7th. They issued a "buy" rating and a $37.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, OrthoPediatrics presently has a consensus rating of "Moderate Buy" and an average target price of $35.83.

OrthoPediatrics Trading Up 1.7%

The company has a quick ratio of 3.68, a current ratio of 7.17 and a debt-to-equity ratio of 0.19. The stock has a fifty day simple moving average of $21.82 and a 200 day simple moving average of $23.51. The firm has a market capitalization of $497.15 million, a P/E ratio of -16.64 and a beta of 1.09.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.13). The firm had revenue of $52.41 million for the quarter, compared to analysts' expectations of $51.68 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. As a group, research analysts forecast that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

Insider Activity

In related news, CFO Fred Hite sold 6,443 shares of OrthoPediatrics stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $160,172.98. Following the completion of the transaction, the chief financial officer now owns 207,989 shares in the company, valued at approximately $5,170,606.54. This trade represents a 3.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO David R. Bailey sold 6,620 shares of OrthoPediatrics stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $164,573.20. Following the completion of the transaction, the chief executive officer now owns 319,155 shares of the company's stock, valued at approximately $7,934,193.30. This represents a 2.03% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,732 shares of company stock worth $589,978 over the last 90 days. Corporate insiders own 32.70% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP grew its position in OrthoPediatrics by 29.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 671,968 shares of the company's stock worth $15,576,000 after acquiring an additional 152,681 shares in the last quarter. HighTower Advisors LLC bought a new stake in OrthoPediatrics in the fourth quarter worth about $268,000. Charles Schwab Investment Management Inc. lifted its stake in OrthoPediatrics by 2.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 136,234 shares of the company's stock worth $3,158,000 after purchasing an additional 3,800 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in OrthoPediatrics by 204.8% in the fourth quarter. JPMorgan Chase & Co. now owns 42,817 shares of the company's stock worth $992,000 after purchasing an additional 28,768 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in OrthoPediatrics by 3.0% in the fourth quarter. Invesco Ltd. now owns 16,363 shares of the company's stock worth $379,000 after purchasing an additional 469 shares during the last quarter. Hedge funds and other institutional investors own 69.05% of the company's stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.